Cargando…

A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)

BACKGROUND: Idiopathic nephrotic syndrome has a relapsing-remitting course in the majority of pediatric patients, demanding vigilant monitoring and self-management. A novel, expert-designed, user-informed mobile application (app), UrApp©, was created to support management tasks, including home urine...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chia-shi, Escoffery, Cam, Patzer, Rachel E., McCracken, Courtney, Ross, Diana, Rheault, Michelle N., Al-Uzri, Amira, Greenbaum, Larry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146890/
https://www.ncbi.nlm.nih.gov/pubmed/32272901
http://dx.doi.org/10.1186/s12882-020-01778-w
_version_ 1783520306044862464
author Wang, Chia-shi
Escoffery, Cam
Patzer, Rachel E.
McCracken, Courtney
Ross, Diana
Rheault, Michelle N.
Al-Uzri, Amira
Greenbaum, Larry A.
author_facet Wang, Chia-shi
Escoffery, Cam
Patzer, Rachel E.
McCracken, Courtney
Ross, Diana
Rheault, Michelle N.
Al-Uzri, Amira
Greenbaum, Larry A.
author_sort Wang, Chia-shi
collection PubMed
description BACKGROUND: Idiopathic nephrotic syndrome has a relapsing-remitting course in the majority of pediatric patients, demanding vigilant monitoring and self-management. A novel, expert-designed, user-informed mobile application (app), UrApp©, was created to support management tasks, including home urine protein monitoring. METHODS: The UrApp Pilot Study (ClinicalTrials.gov, NCT04075656) is a randomized trial comparing UrApp-supported nephrotic syndrome management with standard-of-care with parallel process evaluation of the intervention delivery. Sixty caregivers of children with newly diagnosed, steroid-sensitive nephrotic syndrome will be randomized 1:1 to UrApp-supported care or standard-of-care. Follow-up will be 1 year, with primary outcomes of adherence to urine monitoring and medications assessed at 6 and 12 months. Secondary outcomes at 6 and 12 months include self-efficacy, quality-of-life, hospitalizations and delayed relapse diagnoses. A mixed-methods approach will evaluate UrApp engagement, use retention, features used, user perceptions, and contextual barriers and facilitators of UrApp use. User behavior will be assessed for relationships to the primary and secondary outcomes. A Stakeholder Committee of volunteer trial participants, clinicians, and engineers will examine the trial results and design a pragmatic UrApp-enhanced nephrotic syndrome intervention with potential for wide implementation. The final UrApp intervention will be tested in a user-centered hybrid effectiveness-implementation trial designed with stakeholder input. DISCUSSION: The UrApp Pilot Study examines the efficacy of a novel app designed specifically for nephrotic syndrome. The protocol involves dual efficacy and process evaluation aims to increase efficiency and incorporates the stakeholders’ perspective in formative assessment to inform intervention redesign and the design of a future user-centered trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04075656. Registered on September 2, 2019, https://clinicaltrials.gov/ct2/show/NCT04075656
format Online
Article
Text
id pubmed-7146890
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71468902020-04-18 A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study) Wang, Chia-shi Escoffery, Cam Patzer, Rachel E. McCracken, Courtney Ross, Diana Rheault, Michelle N. Al-Uzri, Amira Greenbaum, Larry A. BMC Nephrol Study Protocol BACKGROUND: Idiopathic nephrotic syndrome has a relapsing-remitting course in the majority of pediatric patients, demanding vigilant monitoring and self-management. A novel, expert-designed, user-informed mobile application (app), UrApp©, was created to support management tasks, including home urine protein monitoring. METHODS: The UrApp Pilot Study (ClinicalTrials.gov, NCT04075656) is a randomized trial comparing UrApp-supported nephrotic syndrome management with standard-of-care with parallel process evaluation of the intervention delivery. Sixty caregivers of children with newly diagnosed, steroid-sensitive nephrotic syndrome will be randomized 1:1 to UrApp-supported care or standard-of-care. Follow-up will be 1 year, with primary outcomes of adherence to urine monitoring and medications assessed at 6 and 12 months. Secondary outcomes at 6 and 12 months include self-efficacy, quality-of-life, hospitalizations and delayed relapse diagnoses. A mixed-methods approach will evaluate UrApp engagement, use retention, features used, user perceptions, and contextual barriers and facilitators of UrApp use. User behavior will be assessed for relationships to the primary and secondary outcomes. A Stakeholder Committee of volunteer trial participants, clinicians, and engineers will examine the trial results and design a pragmatic UrApp-enhanced nephrotic syndrome intervention with potential for wide implementation. The final UrApp intervention will be tested in a user-centered hybrid effectiveness-implementation trial designed with stakeholder input. DISCUSSION: The UrApp Pilot Study examines the efficacy of a novel app designed specifically for nephrotic syndrome. The protocol involves dual efficacy and process evaluation aims to increase efficiency and incorporates the stakeholders’ perspective in formative assessment to inform intervention redesign and the design of a future user-centered trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04075656. Registered on September 2, 2019, https://clinicaltrials.gov/ct2/show/NCT04075656 BioMed Central 2020-04-09 /pmc/articles/PMC7146890/ /pubmed/32272901 http://dx.doi.org/10.1186/s12882-020-01778-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Wang, Chia-shi
Escoffery, Cam
Patzer, Rachel E.
McCracken, Courtney
Ross, Diana
Rheault, Michelle N.
Al-Uzri, Amira
Greenbaum, Larry A.
A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
title A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
title_full A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
title_fullStr A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
title_full_unstemmed A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
title_short A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)
title_sort dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the urapp for childhood nephrotic syndrome management pilot study protocol (urapp pilot study)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146890/
https://www.ncbi.nlm.nih.gov/pubmed/32272901
http://dx.doi.org/10.1186/s12882-020-01778-w
work_keys_str_mv AT wangchiashi adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT escofferycam adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT patzerrachele adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT mccrackencourtney adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT rossdiana adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT rheaultmichellen adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT aluzriamira adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT greenbaumlarrya adualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT wangchiashi dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT escofferycam dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT patzerrachele dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT mccrackencourtney dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT rossdiana dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT rheaultmichellen dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT aluzriamira dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy
AT greenbaumlarrya dualefficacyimplementationtrialofanovelmobileapplicationforchildhoodnephroticsyndromemanagementtheurappforchildhoodnephroticsyndromemanagementpilotstudyprotocolurapppilotstudy